<DOC>
	<DOCNO>NCT02660736</DOCNO>
	<brief_summary>Albiglutide ( Alb ) novel analogue glucagon-like peptide-1 ( GLP-1 ) develop approve treatment type 2 diabetes mellitus . Currently , lyophilize albiglutide diluent provide dual chamber Cartridge ( DCC ) single-dose pen injector , require reconstitution prior use . A liquid formulation albiglutide enable use liquid product ready-to-use single dose auto-injector . To support development liquid auto-injector product , healthy volunteer bioequivalence study conduct compare liquid drug product currently available lyophilized product . This Phase I , randomize , double-blind , double dummy , single-dose , 2-period crossover study healthy volunteer . This study compare pharmacokinetics safety albiglutide 50 mg liquid drug product albiglutide 50 mg commercial lyophilize drug product .</brief_summary>
	<brief_title>Bioequivalence Study Two Albiglutide Drug Products Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Between 18 65 year age . Healthy . Subject nonsmoker . Subject 's body mass index ( BMI ) &gt; =18 kilogram/meter square ( kg/m^2 ) &lt; =30 kg/m^2 Male Female Alanine aminotransferase ( ALT ) &gt; 1.5 x upper limit normal range ( ULN ) Bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percent [ % ] ) . Current chronic history liver disease , know hepatic biliary abnormality QT interval correct heart rate accord Fridericia 's formula ( QTcF ) &gt; 450 millisecond ( msec ) . Systolic blood pressure &gt; =140 millimeter mercury ( mmHg ) Screening ; Diastolic blood pressure &gt; =90 mmHg Screening ; Heart rate &gt; 100 beats/min Screening . estimate glomerular filtration rate ( eGFR ) &lt; =80 milliliter per minute per 1.73 meter square ( mL/min/1.73 m^2 ) ( calculate use Chronic Kidney Disease Epidemiology Collaboration [ CKDEPI ] formula ) Screening . Fasting triglyceride level &gt; 300 milligram per deciliter ( mg/dL ) Screening . History significant cardiovascular pulmonary dysfunction prior Screening . History thyroid dysfunction abnormal ( i.e. , outside normal reference range ) thyroid function test assess thyroid stimulate hormone Screening . History gastrointestinal surgery could influence gastric emptying ( e.g. , gastrectomy , gastric bypass ) . History pancreatitis . Personal family history multiple endocrine neoplasia type 2 . Personal family history medullary carcinoma thyroid . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day . History regular alcohol consumption within 6 month study . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 3 month prior screen . History sensitivity study medication , component thereof history drug allergy . Subject previously receive GLP1 mimetic compound ( eg. , exenatide , liraglutide , lixisenatide , dulaglutide ) . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Subject donate blood excess 500 mL within 56 day prior dose intention donate month complete study . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure 4 new chemical entity within 12 month prior first dose day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Albiglutide</keyword>
	<keyword>Randomized</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>GSK716155</keyword>
	<keyword>Bioequivalence study</keyword>
</DOC>